Flexible Tirzepatide Titration Strategy Aims to Reduce GI Side Effects While Maintaining Weight Loss in Obesity

The treatment landscape for obesity has advanced significantly with medications like tirzepatide, a dual GLP-1R and GIPR agonist, demonstrating substantial weight loss. However, gastrointestinal (GI) side effects, particularly nausea and vomiting, are common during the initial dose escalation phase, often leading to reduced adherence or discontinuation. Current standard-of-care titration protocols are fixed, lacking personalization for individual patient tolerability. This trial addresses the critical gap in evidence for individualized titration strategies that could improve patient experience and long-term treatment outcomes for obesity.

This clinical trial will randomize adult participants with obesity (without diabetes) into two groups: a standard per-label tirzepatide titration arm and a flexible, symptom-guided titration arm. Participants in the flexible group will utilize a click-based dosing method, allowing for smaller, individualized dose increases based on their tolerability. The study duration is 76 weeks, during which participants will attend regular visits for comprehensive safety assessments and outcome measurements. The primary endpoints include the incidence and severity of gastrointestinal adverse events, particularly nausea and vomiting, and overall body weight loss.

As a trial design, this study does not present findings but outlines its primary objectives and hypotheses. The central aim is to determine if a flexible, symptom-guided titration strategy for tirzepatide can significantly reduce the occurrence and severity of gastrointestinal side effects, specifically nausea and vomiting, when compared to the standard per-label titration protocol. Researchers also hypothesize that this individualized approach will achieve weight loss outcomes that are comparable to those observed with standard titration. The study is designed to assess differences in overall tolerability and treatment effectiveness between the two titration methods.

The primary question is whether flexible, symptom-guided titration reduces nausea and vomiting compared with standard per-label titration, while maintaining comparable weight loss. Secondary objectives include evaluating adherence rates, patient satisfaction, and the impact on long-term weight maintenance. The study seeks to provide evidence for a more patient-centric dosing approach that could optimize the therapeutic window of tirzepatide.